Abstract
Leishmaniases are neglected tropical diseases caused by obligate intracellular protozoa of the genus Leishmania. The drugs used in treatment have a high financial cost, a long treatment time, high toxicity, and variable efficacy. 3-Carene (3CR) is a hydrocarbon monoterpene that has shown in vitro activity against some Leishmania species; however, it has low water solubility and high volatility. This study aimed to develop Poloxamer 407 micelles capable of delivering 3CR (P407-3CR) to improve antileishmanial activity. The micelles formulated presented nanometric size, medium or low polydispersity, and Newtonian fluid rheological behavior. 3CR and P407-3CR inhibited the growth of L. (L.) amazonensis promastigote with IC50/48h of 488.1 ± 3.7 and 419.9 ±1.5 mM, respectively. Transmission electron microscopy analysis showed that 3CR induces multiple nuclei and kinetoplast phenotypes and the formation of numerous cytosolic invaginations. Additionally, the micelles were not cytotoxic to L929 cells or murine peritoneal macrophages, presenting activity on intracellular amastigotes. P407-3CR micelles (IC50/72 h = 0.7 ± 0.1 mM) increased the monoterpene activity by at least twice (3CR: IC50/72 h >1.5 mM). These results showed that P407 micelles are an effective nanosystem for delivering 3CR and potentiating antileishmanial activity. More studies are needed to evaluate this system as a potential therapeutic option for leishmaniases.
Keywords: monoterpene, antileishmanial, triblock copolymers, nanostructure, cytotoxicity
1. Introduction
Leishmaniases are neglected infectious diseases caused by protozoa of the genus Leishmania and transmitted by blood-sucking phlebotomine sand flies as a vector-borne disease [1]. Such illnesses are associated with climate and environmental changes, poverty, poor nutrition, poor housing conditions, and the vulnerability of the host’s immune system. It is estimated that 700,000 to 1,000,000 new cases occur annually [2].
Some species of Leishmania have tropism for organs, especially the liver, spleen, and bone marrow, causing visceral leishmaniasis, a severe form of the disease that usually leads to the patient’s death if not treated [3]. However, even in treated patients, the average lethality is around 8% in the Americas [4]. On the other hand, some parasite species have dermal tropism and remain in the cutaneous area at the inoculation site or spread to other integument regions, causing localized cutaneous lesions or even diffused or mucocutaneous lesions [5]. These clinical manifestations in the integument are usually not lethal but can promote deformations and/or scars in large body extensions, and mutilations that directly affect the patient´s quality of life [6].
Despite the various forms of leishmaniases, a limited group of drugs such as pentavalent antimonials, amphotericin B, pentamidine, miltefosine, paromomycin, and some azoles are available for treatment [7]. In general, these drugs have drawbacks that can compromise their efficacy, involving severe side effects, discomfort due to the intramuscular or intravenous route of administration, an extended treatment time and thus high financial costs, variable anti-leishmanial effects, and the imminent risk of the emergence of new resistant strains [8].
The limitations related to the pharmacotherapy of leishmaniases and the absence of other forms of control reinforce the urgency for more effective, safe, and low-cost alternative drugs. Natural products stand out in this context, representing approximately 25% of all drugs currently marketed [9,10,11]. Monoterpenes are secondary metabolites with multiple pharmacological properties [12,13], which have demonstrated in vitro and in vivo activities against different species of Leishmania [14,15,16,17,18].
3-Carene (3CR) is a monoterpene identified in several vegetal species [19], and it is among the main components of pine tree (Pinus genus) and spruce (Piceaabis) oil-resin, natural in temperate regions, and pepper (Piper genus), common in tropical and subtropical areas [20,21]. In previous studies, the leishmanicidal activity of 3CR has been assessed in vitro against Leishmania (L.) donovani (IC50/72 h = 27.0 µg/mL) and Leishmania amazonensis (IC50/24 h = 72.5 µg/mL) promastigotes [22,23]. However, similar to other monoterpenes, 3CR has high hydrophobicity and volatility, rapid metabolism, and consequent rapid elimination in humans, compromising its use as a therapeutic agent [24]. In this scenario, the use of nanotechnological strategies as drug delivery systems is crucial toovercome these limitations.
Poloxamers are triblock copolymers that, in an aqueous medium, can self-organize into nanometric-sized micelles. Micellar systems (micelles, hydrogels, andorganogels) of poloxamer have been used to solve problems such as low solubility and reduced absorption of drugs; additionally, they offer protection against drug degradation, modified release, and improved efficacy [25]. Furthermore, poloxamer micelles have the most reduced dimensions (10 to 200 nm) among the nanosystems used for drug delivery, which favors circulation in the bloodstream, diffusion in distinct tissues, and cell uptake [26,27,28,29]. Therefore, it is particularly relevant for formulations for leishmaniases, as the drugs must reach the parasite in the parasitophorous vacuole within the host macrophages.
Thus, this work aimed to develop and characterize micelles containing 3CR to improve antileishmanial activity while also assessing its primary targets in L. amazonensis promastigotes by electron microscopy.
2. Materials and Methods
2.1. Chemical and Reagents
Poloxamer 407 (P407), 3CR (3,7,7-Trimethyl-bicyclo[4,1,0]hept-3-ene,96.1% pure), amphotericin B, resazurin, MTT salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), the mediums Schneider’s insect, DMEM, and RPMI were purchased from Sigma-Aldrich (St. Louis, MO, USA). All chemicals and solvents were of analytical grade.
2.2. Micelle Preparation
Micelles were prepared by dispersing appropriate amounts of P407 (5.15% w/v) in sterile phosphate-buffered saline (PBS, pH 7.4) under mechanical stirring with a magnetic bar (100 rpm) at room temperature [30]. After one hour of stirring and complete dissolution of the polymer, 3CR was added at a final concentration of 7.3 mM (1 mg/mL) and stirring was continued for another hour. Micelles without the addition of 3CR were also formulated following the same protocol. The formulations obtained (P407 and P407-3CR micelles) were stored and protected from light in an amber bottle and refrigerated at 8 °C. The maximum capacity of P407 micelles (5%) to solubilize 3CR defined the concentration used in the micelles. PBS as a dispersant medium was considered due to the compatibility of this solution with the physiological medium.
2.3. Dynamic Light Scattering (DLS) Analysis
The micelles’ hydrodynamic diameter (HD) and polydispersity index (PDI) were determined by dynamic light scattering (DLS, Dynamic Light Scattering) using the Zetasizer Nano ZS equipment (Malvern Instruments®, Malvern, UK), with a fixed detector at an angle of 173°. Measurements were performed in a quartz cuvette using undiluted samples at 25 and 37 °C [31].
2.4. Rheological Analysis
The rheological characterization of micelles was carried out in a Discovery Hybrid HR-1 rheometer (TA Instruments, New Castle, DE, USA). The flow test was performed using a cone-plate geometry of 60 mm diameter, and a 0.050 mm distance between the clone and the plate, with a 2° angle and a running time of 4 min for each sample. The shear rate ranged from 0 to 200 s−1, keeping the temperature controlled at 25 °C. Each sample was carefully applied to the bottom plate of the rheometer, ensuring minimal shear and allowing a rest time (relaxation of the induced tension before analysis) of one minute before each determination. The data obtained were analyzed using Origin Pro Software v.8 [31].
2.5. Promastigotes Cultivation and Host Cell Cultures Maintenance
L. (L.) amazonensis promastigotes (strain MHOM/BR/77/LTB0016) were cultivated in Schneider’s insect medium (Gibco®, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS), 100 µg/mL of streptomycin, and 100 U/mL of penicillin maintained at 26 °C in a BOD (Biochemical oxygen demand) until the sixth passage.
L929 fibroblasts were cultured in DMEM medium (pH 7.4) supplemented with 10% inactivated FBS and 1% antibiotic solution (5.000U/mL penicillin and5 mg/mL streptomycin) maintained in an atmosphere of 5% CO2 at 37 °C and 95% humidity.
2.6. Antipromastigote Activity
L. (L.) amazonensis promastigotes (1 × 106 cells/mL) in logarithmic phase of growth were distributed in 96-well plates and treated with 3CR or micelles (0.1–3.7 mM) for 48 h at 26 °C. Promastigotes incubated in the absence of the formulation were used as a negative control, and amphotericin B (0.03–1 µM) was used as a positive control. The viable parasites were assessed by resazurin fluorescent assay [32]. After the treatment, resazurin was added to each well at a final concentration of 50 µM, and the plates were again incubated for 2 h at 26 °C. The fluorescence was measured using a spectrophotometer (Biotek, Winooski, VT, USA, model Synergy H1) at 560 nm excitation and 590 nm emission. The concentration that inhibits 50% of the parasites (IC50) was obtained by nonlinear regression of the concentration–response curve using GraphPad Prism 5.0 software. The experiments were performed in triplicates in at least three independent biological experiments.
2.7. Antiamastigote Activity
Resident macrophages from BALB/c mice were obtained by peritoneal washing with 5 mL of cold RPMI medium. The cell suspension was adjusted to 2 × 106 cells/mL (0.4 mL/well), plated in Lab-Tek eight-chamber slides (Nunc, Roskilde, Denmark), and incubated at 37 °C with 5% CO2 for 1 h. Stationary-phase L. (L.) amazonensis promastigotes were added at parasite/macrophage ratio of 3:1 for 3 h. Later, the wells were washed three times to remove non-interiorized parasites and then incubated under the same conditions. After 24 h, the infected macrophages were treated with 3CR, micelles (0.02–2.9 mM), and amphotericin B (0.03–1 µM) for 72 h. Next, the slides were stained using rapidpanoptic stain (Newprov, Curitiba, Brazil), and the infection rate was determined by counting under optical light microscope [32]. The experiments were performed in three biological replicates, with two technical replicates, and the number of amastigotes was determined by counting at least 100 macrophages in each one. The results were expressed as an infection index (% infected macrophage × number of amastigotes/total number of macrophages). The IC50/72 h was determined by nonlinear regression analysis in the software GraphPad Prism 5 [33].
2.8. Cytotoxicity to the Host Cells
Cytotoxicity of 3CR and micelles was evaluated on two distinct mammalian cells. In a first set of experiments, MTT method with modifications was employed [33]. L929 fibroblasts (2 × 104 cells/well) were added to 96-well plates and kept in a 5% CO2 atmosphere at 37 °C for 24 h. These cultures were treated with 0.2 to 3.7 mM of 3CR or only micelles and were incubated under the same conditions for 24 h. Then, the cells were washed with PBS, and 200 µL of MTT solution (0.5 mg/mL) was added per well for 3 h. MTT was removed, and the formazan crystals were solubilized with 200 µL DMSO. Optical density was measured at 570 nm.
Alternatively, murine peritoneal macrophages were employed using the resazurin assay [33]. Resident peritoneal macrophages were collected as described before. The cell suspension was adjusted to 2 × 106 cells/mL, distributed in 96-well plates, and treated with 3CR, micellar systems (0.04–5.9 M), and amphotericin B (0.15–20.0 µM) for 72 h at 37 °C in an atmosphere of 5% CO2. Later, steps similar to those described for the antipromastigote test were carried out. All CC50 values were determined by nonlinear regression of the concentration–response curve using the GraphPad Prism 5.0 program. The experiments were performed in triplicates in at least three independent biological experiments.
In order to compare the biological activity and toxicity to the host, the selectivity index (SI = CC50 72 h/IC50 72 h) was calculated.
2.9. Transmission Electron Microscopy Analysis
L. (L.) amazonensis promastigotes (5 × 106 cells/mL) were treated with 488.1 mM 3CR for 48 h at 26 °C. The parasites were fixed with 2.5% glutaraldehyde diluted in 0.1 M sodium cacodylate buffer (pH 7.2) for 40 min at 25 °C, and then post-fixed with a solution of 1% OsO4 containing 0.8% potassium ferricyanide and 2.5 mM CaCl2 in the same buffer for 20 min at 25 °C. The samples were dehydrated in an ascending acetone series and embedded in PolyBed 812 resin. Ultrathin sections were stained with uranyl acetate and lead citrate and the examination was performed in a Jeol 1200 EX transmission electron microscope (Tokyo, Japan) at National Center for Structural Biology and Bioimaging, Federal University of Rio de Janeiro.
2.10. Statistical Analysis
The analysis of variance (ANOVA) was applied to determine the most relevant results. The values obtained were compared and separated by the Bonferroni test. Statistical analysis was conducted using Graph Pad Prisma 5.0. Values with p < 0.05 were considered significant.
2.11. Ethics Statement
The use of animals and our experimental procedure arein accordance with Brazilian Law 11.794/2008 and regulations of the National Council of Animal Experimentation Control (CONCEA). Mice were housed at a maximum of 4 per cage, kept in a specific-pathogen-free (SPF) room at 20 to 24 °C under a 12 h light and dark cycle, and provided sterilized water and rodent chow ad libitum. All animal procedures were reviewed and approved by Fiocruz Committee of Ethics in Animal Research (L-002/2022), according to resolution 196/96 of the National Health Council of Brazilian Ministry of Health.
3. Results
3.1. Physical–Chemical Characterization of Micelles
3.1.1. Micelles Obtained and Micelle Size
The micelles obtained were initially evaluated by visual inspection and light microscopy. Both micelles’ formulations were transparent, uniform, and colorless, without particulate matter or phase separation. To determine the size of the micelles, the hydrodynamic diameter (HD) and the polydispersion index (PDI) of the micelles were analyzed. These parameters were evaluated under the influence of temperatures at 25 °C (room temperature) and 37 °C (physiological temperature) both before and after 3CR incorporation [31] (Table 1).
Table 1.
Formulations | T 1 (°C) | HD (nm) | PDI | T (°C) | HD (nm) | PDI |
---|---|---|---|---|---|---|
P407 | 25 | 24.16 ± 0.42 | 0.314 ± 0.014 | 37 | 18.48 ± 0.15 | 0.206 ± 0.011 |
P407-3CR | 25 | 26.81 ± 0.82 * | 0.463 ± 0.023 | 37 | 21.17 ± 0.45 * | 0.326 ± 0.027 |
1 T: Temperature.Data represent the mean of three independent experiments ± standard error (SE). * Statistical difference between the micellar system with and without 3CR (p < 0.05).
The micelles presented nanometric sizes that varied from 18.48 to 26.81 nm and PDI from 0.206 to 0.463, relative to a size distribution that varied from monomodal to multimodal. In multimodal samples, HD reflects more than 75% of micelles. The incorporation of 3CR caused a significant increase in HD and PDI, while the increase in temperature caused a reduction in HD and PDI in both micelles, with and without 3CR.
3.1.2. Rheological Behavior
The flow test was carried out to observe the rheological behavior of the micelles with and without 3CR (Figure 1). The micelles presented flow curves in which the shear stress and the shear rate present linear dependence. These data classify the systems as Newtonian fluid [34]. From the linear fit of the curves, it was possible to obtain viscosity values around 2.8 mPa.s and 2.5 mPa.s for P407 and P407-3CR, respectively, indicating that the micelles showed low viscosity and the incorporation of 3CR did not change the flow rate.
3.2. Bioassays
3.2.1. Leishmanicidal Activity in Promastigotes
The antipromastigote effect was evaluated after 48 h of treatment and expressed as IC50/48 h. No statistical differences were observed between P407-3CR micelles and 3CR, indicating that the incorporation of the monoterpene in the micelles maintained the anti-protozoa activity (Figure 2 and Table 2).
Table 2.
Formulations | IC50/48 h (mM) 2 |
---|---|
3CR 1 | 488.1 ± 3.7 3 |
P407 | - |
P407-3CR | 419.9 ± 1.5 |
Amphotericin B | 0.0002 ± 0.1 |
1 3CR: 3-Carene, 2 IC50/48 h: half of the maximum inhibitory effect at 48 h of treatment. 3 Data are expressed as mean ± standard error (n = 3).
3.2.2. Leishmanicidal Activity on Intracellular Amastigotes and Cytotoxicity to Host Cells
The antiamastigote effect was evaluated in infected macrophages after 72 h of treatment. 3CR showed low activity on intracellular amastigotes and it was excluded from the subsequent analysis. Both micelles demonstratedan effect on the parasites; however, P407-3CR was two-fold more active than the pure micelle (Figure 3 and Table 3).
Table 3.
Formulations | IC50/72 h 2 (mM) | CC50/72 h 3 (mM) | SI 4 |
---|---|---|---|
3CR 1 | >1.5 5 | 5.2 ± 0.5 | - |
P407 | 1.4 ± 0.1 | 2.9 ± 0.2 | 2.0 |
P407-3CR | 0.7 ± 0.1 | 3.7 ± 0.1 | 5.2 |
Amphotericin B | 0.0003 ± 0.0 | >0.02 | >66.6 |
1 3CR: 3-Carene. 2 IC50 /72 h: half of the maximum inhibitory effect at 72 h of treatment. 3 CC50 /72 h: half of the maximum cytotoxic effect at 72 h of treatment. 4 SI: Selectivity index determined by equation CC50/IC50 at the same time of treatment. 5 Data are expressed as mean ± standard error.
The cytotoxicity of 3CR and micelles was evaluated in L929 cells (Figure 4) and peritoneal macrophages (Table 3). Using L929 cells model, 3CR was potentially toxic at a concentration above 1.8 mM. However, the P407 and P407-3CR micelles were not cytotoxic, showing viability above 80%, even at the highest concentrations of 3CR.
In primary macrophages, 3CR or micellar systems were also not cytotoxic, even with a longer treatment time (72 h), with CC50/72 h values greater than 2.6 mM (Table 3). As can also be observed in Table 3, P407-3CR showed a higher SI value than the micelle alone, being 5.1-fold more active in the parasite than in the macrophage. The control amphotericin B presented the highest SI value (>66.6).
3.2.3. Ultrastructural Analysis
The transmission electron microscopy technique was employed to assess the possible target organelles of 3CR. Considering that 3CR and 3CR-loaded micelles showed similar antipromastigote activities, the ultrastructural evaluation was only performed on 3CR. The evaluation of untreated promastigotes showed typical morphological features, including the elongated body and classical aspects of organelles such as the mitochondrion, kinetoplast, nucleus, and flagella (Figure 5A,B). The treatment with an IC50/48 h dose of 3CR led to bizarre multiple nuclei and kinetoplast phenotypes, showing an even number of these organelles (usually four per cell) and the formation of innumerous cytosolic elongated invaginations (Figure 6A–F), all suggestive of the impairment of parasite mitosis. The presence of lipid droplets was also easily detected after the treatment with 3CR (Figure 6C–E). Despite the high number of kinetoplasts, thekDNA network was wellpreserved after the treatment (Figure 6C–F).
4. Discussion
Natural products derived from plants, animals, or microorganisms have been playing a relevant role for biotechnological purposes, including in the development of alternative therapeutical strategies, either as a starting point for synthetic modifications or as drugs [11,35]. Aiming to offertherapeutic viability and improve the antileishmanial activity of 3CR, poloxamer P407 micelles loaded with 3CR were developed. This poloxamer has been tested on old drugs (propranolol, lidocaine, and amphotericin B) and new compounds with potential therapeutic (8HQ and clioquinol) [36,37,38,39]. P407 at a concentration of 5.15% was sufficient to form micelles capable of incorporating 7.3 mM of 3CR, resulting in a homogeneous dispersion of the monoterpene in water, similar to that observed by Lucia et al. [40].
The formed micellar structure was initially verified by DLS analysis, showing nanometric aggregates compatible with the size of poloxamer micelles. The micelles were sensitive to temperature, showing smaller sizes at 37 °C. The micelles formulated present polydisperse systems with median or low PDI [41]. According to WU et al. [42], only PDI above 0.5 indicates a wide distribution. The increase in temperature also resulted in a lower PDI. Only the micelles without 3CR at 37 °C presented a monodisperse system. The reduction in the mean diameter and polydispersity of the micelles observed with increasing temperature is related to the dehydration of the polypropylene oxide (PPO) units and the consequent reduction in volume. Similar results were described by Akkari et al. [43], who also formulated a micellar system with P407 and observed lower HD and PDI at a higher temperature.
The incorporation of 3CR into micelles caused an increase in HD and PDI. By chemical affinity, the 3CR must have been accommodated in the micellar nucleus, formed by the poloxamer’s hydrophobic portions (PPO). Hydrophobic compounds with log P above 3.5 (3CR log P 4.38) remain completely solubilized in micelles dispersed in an aqueous medium [44,45]. The incorporation of the compound possibly led to core swelling and an increase in the number of unimers per micelle to compensate for the larger core volume, resulting in a higher aggregation number. Grillo et al. [44] observed an increase in the nucleus radius and aggregation number of P407 micelles after monoterpene linalool was incorporated. Akkari et al. [31] also observed growing HD and PDI after ropivacaine loading into P407 micelles.
An efficient antileishmanial therapy requires the drugs to diffuse widely to eliminate the parasite via the host’s immune system or directly reach the parasite in the infected host’s cells. Therefore, particle size is especially relevant for this kind of approach. Particles ranging from 10 to 70 nm often have good tissue distribution because they spend more time in the bloodstream. Those smaller than 100 nm can be internalized by endocytic activity [27,46]. The size of the micelles developed in this study (18.48 to 26.81 nm) is within the expected range, aiming to keep them in the bloodstream for a longer time, thus resulting in better tissue diffusionand uptake to reach the intracellular parasite.
Micellar dispersions, with and without 3CR, showed Newtonian fluid behavior with low viscosity, as expected. Some studies have shown that Newtonian fluid behavior can be observed even at high concentrations of poloxamers, depending on the temperature [47,48]. Pharmaceutical formulations that behave like Newtonian fluid have broad applicability in terms of route of administration, favoring the use of oral, parenteral, and topical routes conventionally used to administer leishmanicidal drugs.
L. (L.) amazonensis is among the main species that cause cutaneous leishmaniasis in the Americas. It is related to the severe clinical form of diffuse cutaneous leishmaniasis. Furthermore, this parasite species has already been isolated from dogs and humans with visceral leishmaniasis, a clinical manifestation historically associated with L. (L.) infantum [49,50], highlighting its high pathogenic capacity. In previous studies, 3CR, a monoterpene hydrocarbon, showed superior activity in L. (L.) amazonensis compared to several other secondary metabolites that presented more reactive molecular structures, excluding compounds with a phenolic moiety [22]. Furthermore, 3CR is a limonene molecular isomer that shows antileishmanial action [18], justifying its choice for this study. In promastigotes, micelles containing 3CR were the most active in comparison with pure 3CR or empty micelles, presenting the lowest IC50 values. The micelles without the monoterpene also reduced the viability of the parasite, but not enough to determine its IC50. The biological response modification of poloxamers has already been documented for some Leishmania species [28].
Similarly, against the intracellular amastigotes, P407-3CR micelles showed better antiparasitic activity with a SI greater than five. Previous reports with P407 poloxamer micelles have also shown promising results concerning antileishmanial activity. Paromomycin encapsulated in P407 micelles showed higher antipromastigote activity on L. (L.) infantum and L. (L.) major when compared to the free drug [47]. On the other hand, previous studies have shown that drugs loaded in poloxamer micelles only reproduce the leishmanicidal activity of the drug alone but reduce the cytotoxicity. L. (L.)donovani amastigotes treated with amphotericin B in suspension and amphotericin B encapsulated in P407 micelles showed similar results with an IC50/48 h in the range of 0.1 µg/mL; however, the micellar system presented lower cytotoxicity on J774A.1 macrophages [51]. Likewise, Costa et al. [52] encapsulated the monoterpene carvacrol in a P407 micellar system and did not observe a reduction in the IC50/48h value in L. (L.) amazonensis amastigotes, but a significant decrease in cytotoxicity was observed, resulting in a better SI.
The cytotoxicity in this study was evaluated in primary culture macrophages and a fibroblast lineage. Macrophages play a central role in the maintenance, replication, and elimination of Leishmania [53], while fibroblasts are present in most tissues and related to tissue integrity and wound healing [54]. P407 and P407-3CR micelles were not cytotoxic to L929 cells at any evaluated concentrations. Furthermore, the cytotoxicity presented by 3CR in the highest concentrations (1.8 and 3.7 mM) was neutralized when incorporated into the micelles. Poloxamer 407 has shown low cytotoxicity, even at much higher concentrations. In the study by Niyompanich et al. [55], L929 cells were treated with P407 (20%) in water for up to seven days and did not demonstrate cytotoxicity. In this study, 3CR or micellar systems were not toxic to peritoneal macrophages, presenting a high value of CC50. Oyama et al. [28] also observed similar results when treating BALB/c macrophages with 407 micelles at 48 h. Anyway, the SI values for 3CR in micelles or not were far from ideal, much lower than the SI for amphotericin B.
To evaluate the mechanism of action of 3CR in L. (L.) amazonensis, an analysis was carried out bytransmission electron microscopy in treated promastigotes. Our ultrastructural data pointed to the impairment of the parasite division process induced by 3CR, including multiple nuclei and kinetoplasts. Several cytoplasmic invaginations were also observed, suggesting that the cytokinesis of protozoa was not completed. Promastigotes of L. (L.) amazonensis with induced resistance to vinblastine and wild-type parasites treated with vinblastine also showed multinucleated and multilobed cells, which indicate impaired cytokinesis [56]. Similarly, Trypanosoma cruzi treated with vinca alkaloids showed multiple nuclei and kinetoplasts, resulting from a reversible blockage of cytokinesis [57]. Vinblastine is a compound that binds to tubulin, a significant protein in trypanosomatids involved in important events such as nuclear and kinetoplast division and cytokinesis. Taxol, a drug that stabilizes microtubules, also affected cytokinesis and cell cycle progression in G2/M without interfering with the nuclear division of L. (L.) donovani promastigotes [58]. In trypanosomes, cytokinesis is dependent on DNA synthesis but can occur independently of mitosis [59]. Similar mechanisms have been observed in Leishmania, but the order and time in which the events occur vary according to the species [60,61].
Compounds that interact with tubulin have been shown to alter the cell cycle in the G2/M phase and inhibit cytokinesis [62]. It is possible that 3CR interacts with tubulin and/or, due to its lipid characteristic, interacts with membrane sphingolipids, causing cytokinesis inhibition. Castro et al. [63] observed promastigotes of L. (Viannia) braziliensis with three or more nuclei and incomplete cytokinesis after treatment with myriocin, an inhibitor of sphingolipid synthesis. Sphingolipids are a class of lipids involved in many biological processes in trypanosomatids and the inhibition of sphingolipid synthesis showed that these lipids are essential for the conclusion of the parasite’s cytokinesis.
Electron microscopy showed an increase in lipid bodies in parasites treated with 3CR. Godinho et al. [64] also observed the accumulation of lipid bodies in the cytoplasm of L. (L.) amazonensis promastigotes after treatment with the synthetic compound alkyl-phosphatidylcholine-dinitrate (TC95), which suggests an alteration in the phospholipid and sterol content. These authors also identified alterations in the cell cycle, with the majority of the cells arrested in the G1 phase and a significant increase in the number of cells in the G2 phase. These aberrant phenotypes were unable to complete cytokinesis and prevent the start of mitosis, as seen through electron microscopy [64].
A pattern of changes similar to our results was observed in L. (L.) amazonensis promastigotes after the treatment with an alkaloid β-carboline (β-CB). The accumulation of lipid bodies, cells with three or more nuclei, and the inhibition of cytokinesis without interfering with the duplication of cell structures were observed. The alkaloid impairs cytokinesis, preventing parasite proliferation through acytostatic effect [60]. Considering our ultrastructural analysis and comparing similar results obtained in other studies [60], it is possible that 3CR performs its antileishmanial effect by cytostatic and not by cytotoxic. However, several other trials are needed to confirm this hypothesis.
5. Conclusions
P407-3CR micelles demonstrated activity against both promastigotes and intracellular amastigotes. The activity against promastigotes was similar to that observed by 3CR alone. However, the activity against amastigotes was increased by P407 micelles, suggesting that 3CR reached the parasite within the parasitophorous vacuole. The P407-3CR micelles could also reduce the cytotoxicity in both fibroblast and macrophage cells compared to 3CR alone. The first assessment of its mechanism of action pointed to the interference of the cell division process, as evidenced by our ultrastructural data.
Author Contributions
Conceptualization, A.R.S.T.S. and S.S.D.; methodology, S.S.D., R.S., V.H.V.S. and R.F.S.M.-B.; investigation, A.R.S.T.S., A.M.B.C., V.V.A.-N. and A.d.J.S.; resources, S.S.D., R.S., V.H.V.S. and R.d.S.N.; writing—original draft preparation, A.R.S.T.S. and A.M.B.C.; writing—review and editing, S.S.D., R.S., E.C.T.-S., S.J., R.d.S.N. and R.F.S.M.-B.; supervision, S.S.D.; project administration, S.S.D.; funding acquisition, S.S.D. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.
Conflicts of Interest
The authors declare no conflict of interest.
Funding Statement
This research was funded by the Coordination for the Improvement of Higher Education Personnel—Brazil (CAPES)—Financing Code 001 and FAPITEC/SE—the Research and Technological Innovation Support Foundation of the State of Sergipe (Grant CAPES/FAPITEC 10/2016—PROMOB, Process 88881.157707/2017-01). SSD and RFSMB are research fellows (Bolsa de ProdutividadeemPesquisa) from the Brazilian National Council of Research (CNPq). RFSMB was supported by FIOCRUZ and FAPERJ grants.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Brindha J., Balamurali M.M., Chanda K. An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases. Front. Chem. 2021;9:622286. doi: 10.3389/fchem.2021.622286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.WHO Leishmaniasis. [(accessed on 1 March 2023)]. Available online: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis.
- 3.Mann S., Frasca K., Scherrer S., Henao-Martínez A.F., Newman S., Ramanan P., Suarez J.A. A Review of Leishmaniasis: Current Knowledge and Future Directions. Curr. Trop. Med. Rep. 2021;8:121–132. doi: 10.1007/s40475-021-00232-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.PAHO WHO Leishmaniasis: Epidemiological Report for the Americas. Dec 12, 2022. [(accessed on 1 March 2023)]. No. 11. Available online: https://iris.paho.org/handle/10665.2/56831.
- 5.Burza S., Croft S.L., Boelaert M. Leishmaniasis. Lancet. 2018;392:951–970. doi: 10.1016/S0140-6736(18)31204-2. [DOI] [PubMed] [Google Scholar]
- 6.Bailey F., Mondragon-Shem K., Haines L.R., Olabi A., Alorfi A., Ruiz-Postigo J.A., Alvar J., Hotez P., Adams E.R., Vélez I.D., et al. Cutaneous Leishmaniasis and Co-Morbid Major Depressive Disorder: A Systematic Review with Burden Estimates. PLoS Negl. Trop. Dis. 2019;13:e0007092. doi: 10.1371/journal.pntd.0007092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Roatt B.M., de Oliveira Cardoso J.M., De Brito R.C.F., Coura-Vital W., de Oliveira Aguiar-Soares R.D., Reis A.B. Recent Advances and New Strategies on Leishmaniasis Treatment. Appl. Microbiol. Biotechnol. 2020;104:8965–8977. doi: 10.1007/s00253-020-10856-w. [DOI] [PubMed] [Google Scholar]
- 8.Scorza B.M., Carvalho E.M., Wilson M.E. Cutaneous Manifestations of Human and Murine Leishmaniasis. Int. J. Mol. Sci. 2017;18:1296. doi: 10.3390/ijms18061296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Newman D.J., Cragg G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 2020;83:770–803. doi: 10.1021/acs.jnatprod.9b01285. [DOI] [PubMed] [Google Scholar]
- 10.Savoia D. Review Recent Updates and Perspectives on Leishmaniasis. J. Infect. Dev. Ctries. 2015;9:588–596. doi: 10.3855/jidc.6833. [DOI] [PubMed] [Google Scholar]
- 11.Mushtaq S., Abbasi B.H., Uzair B., Abbasi R. Natural Products as Reservoirs of Novel Therapeutic Agents. EXCLI J. 2018;17:420–451. doi: 10.17179/excli2018-1174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wojtunik-Kulesza K.A., Kasprzak K., Oniszczuk T., Oniszczuk A. Natural Monoterpenes: Much More than Only a Scent. Chem. Biodivers. 2019;16:e1900434. doi: 10.1002/cbdv.201900434. [DOI] [PubMed] [Google Scholar]
- 13.Koziol A., Stryjewska A., Librowski T., Salat K., Gawel M., Moniczewski A., Lochynki S. An Overview of the Pharmacological Properties and Potential Applications of Natural Monoterpenes. Mini-Rev. Med. Chem. 2014;14:1156–1168. doi: 10.2174/1389557514666141127145820. [DOI] [PubMed] [Google Scholar]
- 14.Medeiros M.G.F., da Silva A.C., Citó A.M.d.G.L., Borges A.R., deLima S.G., Lopes J.A.D., Figueiredo R.C.B.Q. In Vitro Antileishmanial Activity and Cytotoxicity of Essential Oil from Lippia Sidoides Cham. Parasitol. Int. 2011;60:237–241. doi: 10.1016/j.parint.2011.03.004. [DOI] [PubMed] [Google Scholar]
- 15.de Morais S.M., Vila-Nova N.S., Bevilaqua C.M., Rondon F.C., Lobo C.H., Moura A.D., Sales A.D., Rodrigues A.P., de Figuereido J.R., Campello C.C., et al. Thymol and Eugenol Derivatives as Potential Antileishmanial Agents. Bioorg. Med. Chem. 2014;22:6250–6255. doi: 10.1016/j.bmc.2014.08.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Machado M., Pires P., Dinis A.M., Santos-rosa M., Alves V., Salgueiro L., Cavaleiro C. Monoterpenic Aldehydes as Potential Anti- Leishmania Agents: Activity of Cymbopogon Citratus and Citral on L. Infantum, L. Tropica and L. Major. Exp. Parasitol. 2012;130:223–231. doi: 10.1016/j.exppara.2011.12.012. [DOI] [PubMed] [Google Scholar]
- 17.Youssef M.R., Moghaddas E., Tabari M.A., Moghadamnia A.A., Hosseini S.M., Farash B.R.H., Ebrahimi M.A., Mousavi N.N., Fata A., Maggi F., et al. In Vitro and In Vivo Effectiveness of Carvacrol, Thymol and Linalool against Leishmania Infantum. Molecules. 2019;11:2072. doi: 10.3390/molecules24112072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Arruda D.C., Miguel D.C., Yokoyama-yasunaka J.K.U., Katzin A.M., Uliana S.R.B. Inhibitory Activity of Limonene against Leishmania Parasites in Vitro and in Vivo. Biomed. Pharmacother. 2009;63:643–649. doi: 10.1016/j.biopha.2009.02.004. [DOI] [PubMed] [Google Scholar]
- 19.Api A.M., Belmonte F., Belsito D., Botelho D., Bruze M., Burton G.A., Buschmann J., Dagli M.L., Date M., Dekant W., et al. RIFM Fragrance Ingredient Safety Assessment, δ-3-Carene, CAS Registry Number 13466-78-9. Food Chem. Toxicol. 2018;122:S771–S779. doi: 10.1016/j.fct.2018.11.049. [DOI] [PubMed] [Google Scholar]
- 20.Edman K., Löfstedt H., Berg P., Eriksson K., Axelsson S., Bryngelsson I., Fedeli C. Exposure Assessment to α and β-Pinene, Δ3-Carene and Wood Dust in Industrial Production of Wood Pellets. Ann. Occup. Hyg. 2003;47:219–226. doi: 10.1093/annhyg/meg024. [DOI] [PubMed] [Google Scholar]
- 21.Wang M., Chittiboyina A.G., Parcher J.F., Ali Z., Ford P., Zhao J., Avula B., Wang Y.H., Khan I.A. Piper Nigrum Oil—Determination of Selected Terpenes for Quality Evaluation. Planta Med. 2019;85:185–194. doi: 10.1055/a-0782-0548. [DOI] [PubMed] [Google Scholar]
- 22.Silva A.R.S.T., Scher R., Santos F.V., Ferreira S.R., Cavalcanti S.C.H., Correa C.B., Bueno L.L., Alves R.J., Souza D.P., Fujiwara R.T., et al. Leishmanicidal Activity and Structure-Activity Relationships of Essential Oil Constituents. Molecules. 2017;22:815. doi: 10.3390/molecules22050815. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Zheljazkov V.D., Cantrell C.L., Tekwani B., Khan S.I. Content, Composition, and Bioactivity of the Essential Oils of Three Basil Genotypes as a Function of Harvesting. J. Agric. Food Chem. 2008;56:380–385. doi: 10.1021/jf0725629. [DOI] [PubMed] [Google Scholar]
- 24.Schmidt L., Belov V.N., Göen T. Human Metabolism of Delta3-Carene and Renal Elimination of Delta3-Caren-10-Carboxylic Acid (Chaminic Acid) after Oral Administration. Arch. Toxicol. 2015;89:381–392. doi: 10.1007/s00204-014-1251-5. [DOI] [PubMed] [Google Scholar]
- 25.Silva A., Costa A., Jain S., Coelho E., Fujiwara R., Scher R., Nunes R., Dolabella S. Application of Poloxamers for the Development of Drug Delivery System to Treat Leishmaniasis: A Review. Curr. Drug Targets. 2020;22:296–309. doi: 10.2174/1389450121666201106145022. [DOI] [PubMed] [Google Scholar]
- 26.Almeida M., Magalhães M., Veiga F., Figueiras A. Poloxamers, Poloxamines and Polymeric Micelles: Definition, Structure and Therapeutic Applications in Cancer. J. Polym. Res. 2018;25:1–14. doi: 10.1007/s10965-017-1426-x. [DOI] [Google Scholar]
- 27.Lu Y., Zhang E., Yang J., Cao Z. Strategies to Improve Micelle Stability for Drug Delivery. Nano Res. 2018;11:4985–4998. doi: 10.1007/s12274-018-2152-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Oyama J., Lera-Nonose D.S.S.L., Ramos-Milaré Á.C.F.H., Padilha Ferreira F.B., de Freitas C.F., Caetano W., Hioka N., Silveira T.G.V., Lonardoni M.V.C. Potential of Pluronics® P-123 and F-127 as Nanocarriers of Anti-Leishmania Chemotherapy. Acta Trop. 2019;192:11–21. doi: 10.1016/j.actatropica.2019.01.008. [DOI] [PubMed] [Google Scholar]
- 29.Pellosi D.S., Moret F., Fraix A., Marino N., Maiolino S., Gaio E., Hioka N., Reddi E., Sortino S., Quaglia F. Pluronic® P123/F127 Mixed Micelles Delivering Sorafenib and Its Combination with Verteporfin in Cancer Cells. Int. J. Nanomed. 2016;11:4479–4494. doi: 10.2147/IJN.S103344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Pereira G.G., Dimer F.A., Guterres S.S., Kechinski C.P., Granada J.E., Cardozo N.S.M. Formulation and Chracterization of Poloxamer 407: Thermoreversible Gel Containing Polymeric Microparticles and Hyaluronic Acid. Quim. Nova. 2013;36:1121–1125. doi: 10.1590/S0100-40422013000800008. [DOI] [Google Scholar]
- 31.Akkari A.C.S., Papini J.Z.B., Garcia G.K., Franco M.K.K.D., Cavalcanti L.P., Gasperini A., Alkschbirs M.I., Yokaichyia F., De Paula E., Tófoli G.R., et al. Poloxamer 407/188 Binary Thermosensitive Hydrogels as Delivery Systems for Infiltrative Local Anesthesia: Physico-Chemical Characterization and Pharmacological Evaluation. Mater. Sci. Eng. C. 2016;68:299–307. doi: 10.1016/j.msec.2016.05.088. [DOI] [PubMed] [Google Scholar]
- 32.Andrade-Neto V.V., Cunha-Júnior E.F., Canto-Cavalheiro M.M., Atella G.C., Fernandes T.A., Costa P.R., Torres-Santos E.C. Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis. Antimicrob. Agents Chemother. 2016;60:6844–6852. doi: 10.1128/AAC.01545-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Andrade-Neto V.V., da Silva Pacheco J., Inácio J.D., Almeida-Amaral E.E., Torres-Santos E.C., Cunha-Junior E.F. Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis. Front. Pharmacol. 2021;12:636265. doi: 10.3389/fphar.2021.636265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Shamana H., Grossutti M., Papp-Szabo E., Miki C., Dutcher J.R. Unusual Polysaccharide Rheology of Aqueous Dispersions of Soft Phytoglycogen Nanoparticles. Soft Matter. 2018;14:6496–6505. doi: 10.1039/C8SM00815A. [DOI] [PubMed] [Google Scholar]
- 35.Schmitt E.K., Hoepfner D., Krastel P. Natural Products as Probes in Pharmaceutical Research. J. Ind. Microbiol. Biotechnol. 2016;43:249–260. doi: 10.1007/s10295-015-1691-9. [DOI] [PubMed] [Google Scholar]
- 36.Perinelli D.R., Cespi M., Pucciarelli S., Casettari L., Palmieri G.F., Bonacucina G. Effect of Phosphate Buffer on the Micellisation Process of Poloxamer 407: Microcalorimetry, Acoustic Spectroscopy and Dynamic Light Scattering (DLS) Studies. Colloids Surfaces A Physicochem. Eng. Asp. 2013;436:123–129. doi: 10.1016/j.colsurfa.2013.06.002. [DOI] [Google Scholar]
- 37.Mendonça D.V.C., Lage L.M.R., Lage D.P., Chávez-Fumagalli M.A., Ludolf F., Roatt B.M., Menezes-Souza D., Faraco A.A.G., Castilho R.O., Tavares C.A.P., et al. Poloxamer 407 (Pluronic® F127)-Based Polymeric Micelles for Amphotericin B: In Vitro Biological Activity, Toxicity and in Vivo Therapeutic Efficacy against Murine Tegumentary Leishmaniasis. Exp. Parasitol. 2016;169:34–42. doi: 10.1016/j.exppara.2016.07.005. [DOI] [PubMed] [Google Scholar]
- 38.dos Lage L.M.R., Barichello J.M., Lage D.P., Mendonça D.V.C., Carvalho A.M.R.S., Rodrigues M.R., Menezes-Souza D., Roatt B.M., Alves R.J., Tavares C.A.P., et al. An 8-Hydroxyquinoline-Containing Polymeric Micelle System Is Effective for the Treatment of Murine Tegumentary Leishmaniasis. Parasitol. Res. 2016;115:4083–4095. doi: 10.1007/s00436-016-5181-4. [DOI] [PubMed] [Google Scholar]
- 39.Tavares G.S.V., Mendonça D.V.C., Miyazaki C.K., Lage D.P., Soyer T.G., Carvalho L.M., Ottoni F.M., Dias D.S., Ribeiro P.A.F., Antinarelli L.M.R., et al. A Pluronic® F127-Based Polymeric Micelle System Containing an Antileishmanial Molecule Is Immunotherapeutic and Effective in the Treatment against Leishmania Amazonensis Infection. Parasitol. Int. 2019;68:63–72. doi: 10.1016/j.parint.2018.10.005. [DOI] [PubMed] [Google Scholar]
- 40.Lucia A., Toloza A.C., Guzmán E., Ortega F., Rubio R.G. Novel Polymeric Micelles for Insect Pest Control: Encapsulation of Essential Oil Monoterpenes inside a Triblock Copolymer Shell for Head Lice Control. PeerJ. 2017;5:e3171. doi: 10.7717/peerj.3171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Kulthe S.S., Inamdar N.N., Choudhari Y.M., Shirolikar S.M., Borde L.C., Mourya V.K. Mixed Micelle Formation with Hydrophobic and Hydrophilic Pluronic Block Copolymers: Implications for Controlled and Targeted Drug Delivery. Colloids Surf. B Biointerfaces. 2011;88:691–696. doi: 10.1016/j.colsurfb.2011.08.002. [DOI] [PubMed] [Google Scholar]
- 42.Wu L., Zhang J., Watanabe W. Physical and Chemical Stability of Drug Nanoparticles. Adv. Drug Deliv. Rev. 2011;63:456–469. doi: 10.1016/j.addr.2011.02.001. [DOI] [PubMed] [Google Scholar]
- 43.Akkari A.C.S., Campos E.V.R., Keppler A.F., Fraceto L.F., de Paula E., Tófoli G.R., de Araujo D.R. Budesonide-Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Binary Poloxamer 407/403 System for Ulcerative Colitis Treatment: A Physico-Chemical Study from Micelles to Hydrogels. Colloids Surf. B Biointerfaces. 2016;138:138–147. doi: 10.1016/j.colsurfb.2015.11.048. [DOI] [PubMed] [Google Scholar]
- 44.Grillo I., Morfin I., Prévost S.F. Structural Characterization of Pluronic Micelles Swollen with Perfume Molecules. Langmuir. 2018;34:13395–13408. doi: 10.1021/acs.langmuir.8b03050. [DOI] [PubMed] [Google Scholar]
- 45.Fischer E., Fieber W., Navarro C., Sommer H., Benczédi D., Velazco M.I., Schönhoff M. Partitioning and Localization of Fragrances in Surfactant Mixed Micelles. J. Surfactants Deterg. 2009;12:73–84. doi: 10.1007/s11743-008-1104-4. [DOI] [Google Scholar]
- 46.Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic Block Copolymers as Novel Polymer Therapeutics for Drug and Gene Delivery. J. Control. Release. 2002;82:189–212. doi: 10.1016/S0168-3659(02)00009-3. [DOI] [PubMed] [Google Scholar]
- 47.Brugués A.P., Naveros B.C., Calpena Campmany A.C., Pastor P.H., Saladrigas R.F., Lizandra C.R. Developing Cutaneous Applications of Paromomycin Entrapped in Stimuli-Sensitive Block Copolymer Nanogel Dispersions. Nanomedicine. 2015;10:227–240. doi: 10.2217/nnm.14.102. [DOI] [PubMed] [Google Scholar]
- 48.Pasquino R., Droghetti H., Carbone P., Mirzaagha S., Grizzuti N., Marchisio D. An Experimental Rheological Phase Diagram of a Tri-Block Co-Polymer in Water Validated against Dissipative Particle Dynamics Simulations. Soft Matter. 2019;15:1396–1404. doi: 10.1039/C8SM01959B. [DOI] [PubMed] [Google Scholar]
- 49.Freitas de Souza C.D., Calabrese K.D., Abreu Silva A.L., Pereira Carvalho L.O., de Oliveira Cardoso F., Moraes Cavalheiros Dorval M.E., Teruya Oshiro E., Quaresma P.F., Ferreira Gontijo C.M., da Silva Pacheco R., et al. Leishmania Amazonensis Isolated from Human Visceral Leishmaniasis: Histopathological Analysis and Parasitological Burden in Different Inbred Mice. Histol. Histopathol. 2018;33:705–716. doi: 10.14670/HH-11-965. [DOI] [PubMed] [Google Scholar]
- 50.Sanches L.D., Martini C.C., Nakamura A.A., Santiago M.E., Dolabela de Lima B., Lima V.M. Natural Canine Infection by Leishmania Infantum and Leishmania Amazonensis and Their Implications for Disease Control. Rev. Bras. Parasitol. Veterinária. 2016;25:465–469. doi: 10.1590/s1984-29612016071. [DOI] [PubMed] [Google Scholar]
- 51.Singh P.K., Pawar V.K., Jaiswal A.K., Singh Y., Srikanth C.H., Chaurasia M., Bora H.K., Raval K., Meher J.G., Gayen J.R., et al. Chitosan Coated PluronicF127 Micelles for Effective Delivery of Amphotericin B in Experimental Visceral Leishmaniasis. Int. J. Biol. Macromol. 2017;105:1220–1231. doi: 10.1016/j.ijbiomac.2017.07.161. [DOI] [PubMed] [Google Scholar]
- 52.Costa A.M.B., Silva A.R.S.T., de Santos A.J., Galvão J.G., Andrade-Neto V.V., Torres-Santos E.C., Ueki M.M., Almeida L.E., Sarmento V.H.V., Dolabella S.S., et al. Thermosensitive System Formed by Poloxamers Containing Carvacrol: An Effective Carrier System against Leishmania Amazonensis. Acta Trop. 2023;237:106744. doi: 10.1016/j.actatropica.2022.106744. [DOI] [PubMed] [Google Scholar]
- 53.Bogdan C., Donhauser N., Döring R., Röllinghoff M., Diefenbach A., Rittig M.G. Fibroblasts as Host Cells in Latent Leishmaniosis. J. Exp. Med. 2000;191:2121–2129. doi: 10.1084/jem.191.12.2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Lynch M.D., Watt F.M. Fibroblast Heterogeneity: Implications for Human Disease. J. Clin. Investig. 2018;128:26–35. doi: 10.1172/JCI93555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Niyompanich J., Chuysinuan P., Pavasant P., Supaphol P. Development of Thermoresponsive Poloxamer in Situ Gel Loaded with Gentamicin Sulfate for Cavity Wounds. J. Polym. Res. 2021;28:1–13. doi: 10.1007/s10965-020-02352-6. [DOI] [Google Scholar]
- 56.Borges V.M., Lopes U.G., De Souza W., Vannier-Santos M.A. Cell Structure and Cytokinesis Alterations in Multidrug-Resistant Leishmania (Leishmania) Amazonensis. Parasitol. Res. 2005;95:90–96. doi: 10.1007/s00436-004-1248-8. [DOI] [PubMed] [Google Scholar]
- 57.Grellier P., Sinou V., Garreau-De Loubresse N., Bylèn E., Boulard Y., Schrével J. Selective and Reversible Effects of Vinca Alkaloids on Trypanosoma Cruzi Epimastigote Forms: Blockage of Cytokinesis without Inhibition of the Organelle Duplication. Cell Motil. Cytoskeleton. 1999;42:36–47. doi: 10.1002/(SICI)1097-0169(1999)42:1<36::AID-CM4>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
- 58.Moulay L., Robert-Gero M., Brown S., Gendron M.C., Tournier F. Sinefungin and Taxol Effects on Cell Cycle and Cytoskeleton of Leishmania Donovani Promastigotes. Exp. Cell Res. 1996;226:283–291. doi: 10.1006/excr.1996.0229. [DOI] [PubMed] [Google Scholar]
- 59.Ploubidou A., Robinson D.R., Docherty R.C., Ogbadoyi E.O., Gull K. Evidence for Novel Cell Cycle Checkpoints in Trypanosomes: Kinetoplast Segregation and Cytokinesis in the Absence of Mitosis. J. Cell Sci. 1999;112:4641–4650. doi: 10.1242/jcs.112.24.4641. [DOI] [PubMed] [Google Scholar]
- 60.Stefanello T.F., Panice M.R., Ueda-Nakamura T., Sarragiotto M.H., Auzély-Velty R., Nakamura C.V. N-Butyl-[1-(4-Methoxy)Phenyl-9H-β-Carboline]-3-Carboxamide Prevents Cytokinesis in Leishmania Amazonensis. Antimicrob. Agents Chemother. 2014;58:7112–7120. doi: 10.1128/AAC.03340-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Ambit A., Woods K.L., Cull B., Coombs G.H., Mottram J.C. Morphological Events during the Cell Cycle of Leishmania Major. Eukaryot. Cell. 2011;10:1429–1438. doi: 10.1128/EC.05118-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Havens C.G., Bryant N., Asher L., Lamoreaux L., Perfetto S., Brendle J.J., Werbovetz K.A. Cellular Effects of Leishmanial Tubulin Inhibitors on L. Donovani. Mol. Biochem. Parasitol. 2000;110:223–236. doi: 10.1016/S0166-6851(00)00272-3. [DOI] [PubMed] [Google Scholar]
- 63.Castro E.V., Yoneyama K.G., Haapalainen E.F., Toledo M.S., Takahashi H.K., Straus A.H. Myriocin, a Serine Palmitoyltransferase Inhibitor, Blocks Cytokinesis in Leishmania (Viannia) Braziliensis Promastigotes. J. Eukaryot. Microbiol. 2013;60:377–387. doi: 10.1111/jeu.12043. [DOI] [PubMed] [Google Scholar]
- 64.Godinho J.L.P., Georgikopoulou K., Calogeropoulou T., de Souza W., Rodrigues J.C.F. A Novel Alkyl Phosphocholine-Dinitroaniline Hybrid Molecule Exhibits Biological Activity in Vitro against Leishmania Amazonensis. Exp. Parasitol. 2013;135:153–165. doi: 10.1016/j.exppara.2013.06.015. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.